Kraig Biocraft Laboratories, Inc. announced that Kraig Labs is now in production with its BAM-1 recombinant spider silk hybrids. The Company originally planned this launch for July, but the resounding successes of the production trials positioned Kraig Labs to accelerate its 2024 production schedule. This production cycle serves as a critical transition for the Company's commercialization of sustainable and cost-effective spider silk production.

This announcement marks the Company's first transition of true production hybrids to the manufacturing environment. This rearing cycle also represents more than a 10X increase in production over the spring trials and is the largest single batch of spider silk production in the Company's operating history. The BAM-1 hybrids exhibited an excellent hatching yield and continue to show strong and uniform growth.

The Company's team has been closely monitoring their health and is proud to report that, just like the spring trials, it has not observed any sign of disease or weakness within the colony. The BAM-1 hybrid were created by integrating the Company's recombinant spider silk technology, Dragon Silk, into two robust commercial silkworm strains. These two silkworm strains created the parental lines that, when combined, produce the BAM-1 hybrids.

The BAM-1 Hybrid result in the largest cocoons and most robust silkworms. This, in turn, results in higher silk yield and improved production efficiency, while maintaining fiber material performance, as the Company scales up its spider silk production operations. Over the coming weeks, the Company will provide additional updates on this production cycle and its plans for continued production growth and end-market developments.